TAPI d'InSolution-2

Non disponible en dehors du Royaume-Uni et de l'Irlande

General description

A hydroxamate-based inhibitor of matrix metalloproteinases and TACE (TNF-α convertase; ADAM17). Inhibits the activation-dependent shedding of L-selectin from neutrophils, eosinophils, and lymphocytes as well as phenylarsine oxide (PAO)-induced shedding in neutrophils. Also blocks the shedding of several cell surface proteins such as pro-TGF-α, IL-6 receptor α-subunit, and β-amyloid precursor protein. Reported to inhibit TNF-α release and impart protection against aspirin-induced gastric mucosal injury. Acts as a weak inhibitor of angiotensin converting enzyme (IC₅₀ = 18 µM).

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Bennett, T.A., et al. 2000. J. Immunol.164, 4120.Fiorucci, S., et al. 1998. Aliment. Pharmacol. Ther.12, 1139.Hooper, N.M., et al. 1997. Biochem. J.321, 265.Parvathy, S., et al. 1997. Biochem. J.327, 37.Arribas, J., et al. 1996. J. Biol. Chem.271, 11376.

Packaging

Packaged under inert gas

1 mg in Glass bottle

Physical form

A 10 mM (1 mg/241 µL) sterile-filtered solution of TAPI-2 (Cat. No. 579052) in H₂O.

Reconstitution

Following initial thaw, aliquot and freeze (-20°C). Aliquots are stable for up to 3 months at -20°C.

Warning

Toxicity: Standard Handling (A)